PT-141 (Bremelanotide): The FDA-Approved Peptide
Sexual Health Peptides
1,247 women in Phase 3 trials
Bremelanotide (Vyleesi) became the first peptide approved for hypoactive sexual desire disorder in 2019, working through a brain-based mechanism entirely different from Viagra.
Kingsberg et al., Obstetrics and Gynecology, 2019
Kingsberg et al., Obstetrics and Gynecology, 2019
View as imageIn June 2019, the FDA approved bremelanotide under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It was not a small molecule. It was not a hormone. It was a synthetic peptide, seven amino acids long, that activates melanocortin receptors in the brain to increase sexual desire.[1] That made PT-141 the first centrally-acting peptide drug approved for any sexual dysfunction, and it works through a mechanism that has nothing in common with Viagra or any other erectile dysfunction drug. The Vyleesi clinical evidence article covers the Phase 3 trial data in depth. This article covers PT-141's full story: from an accidental discovery involving tanning peptides to a controversial but real FDA approval.
Key Takeaways
- PT-141 (bremelanotide/Vyleesi) was approved in June 2019 for HSDD in premenopausal women, making it the only FDA-approved peptide for low sexual desire (Dhillon and Keam, Drugs, 2019)
- Two Phase 3 trials (RECONNECT) enrolling 1,247 women showed bremelanotide 1.75 mg improved desire scores and reduced sexual distress compared to placebo over 24 weeks (Kingsberg et al., 2019)
- PT-141 activates melanocortin MC3R and MC4R receptors in the hypothalamus, increasing dopamine release in brain regions controlling sexual motivation (Pfaus et al., CNS Spectrums, 2022)
- The drug originated from Melanotan II, a tanning peptide that unexpectedly caused erections in male volunteers during a 1999 University of Arizona trial (Wessells et al., 2000)
- Long-term safety data over 52 weeks showed the most common side effect was nausea (40% of patients), with 18% discontinuing due to adverse reactions (Simon et al., 2019)
- A 2021 reanalysis argued the clinical effect size was modest, with the average improvement translating to roughly one additional satisfying sexual event per month (Spielmans, 2021)
The Accidental Discovery
PT-141's origin has nothing to do with sexual dysfunction research. In the late 1990s, researchers at the University of Arizona were studying Melanotan II, a synthetic analog of alpha-melanocyte stimulating hormone (alpha-MSH) designed to produce sunless tanning. During early human trials, a male volunteer self-injected Melanotan II and experienced an eight-hour erection. Wessells and colleagues published the observation in 2000, documenting that the melanocortin agonist produced dose-dependent erectile responses in healthy men alongside the expected skin darkening.[2]
Mac Hadley, the melanocortin researcher who first characterized the sexual effects, later wrote that the discovery "was serendipitous in the truest sense," noting that the connection between skin pigmentation pathways and sexual arousal had not been predicted by any existing theory.[3] The article on how melanocortin pathways connect skin pigment and sexual arousal explores that biological link in detail.
Palatin Technologies licensed the technology and developed PT-141 (bremelanotide) as a derivative of Melanotan II, stripped of most tanning activity but retaining the sexual effects. The differences between Melanotan I and Melanotan II, and the controversy surrounding unregulated tanning peptides, are covered separately.
How PT-141 Works in the Brain
PT-141 is a cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) that acts as an agonist at melanocortin 3 (MC3R) and melanocortin 4 (MC4R) receptors. These receptors sit in the hypothalamus and limbic system, brain regions that regulate motivation, reward, and sexual behavior.[4]
Molinoff and colleagues at Palatin published the first comprehensive characterization of PT-141's mechanism in 2003. They demonstrated that the peptide increased sexual motivation in animal models without affecting blood pressure at therapeutic doses, distinguishing it from Melanotan II which caused transient hypertension.[5]
Pfaus and colleagues mapped the neurobiology more precisely in 2022 using fMRI. Bremelanotide activated presynaptic MC4R receptors on neurons in the medial preoptic area (mPOA) of the hypothalamus, triggering dopamine release into circuits that govern sexual desire and arousal. This is a fundamentally different mechanism from PDE5 inhibitors like sildenafil (Viagra), which increase blood flow to genital tissue without affecting desire or motivation.[4] The dedicated comparison is in the PT-141 vs PDE5 inhibitors article. The bremelanotide mechanism article covers the neuroscience in greater depth.
The RECONNECT Phase 3 Trials
The FDA approval rested on two identical, randomized, double-blind, placebo-controlled Phase 3 trials collectively called RECONNECT. Kingsberg and colleagues published the results in Obstetrics and Gynecology in 2019.[6]
Design: 1,247 premenopausal women with acquired, generalized HSDD were randomized 1:1 to bremelanotide 1.75 mg or placebo, self-injected subcutaneously as needed before sexual activity, for 24 weeks. The mean age was 39 years. Participants used the drug an average of 2-3 times per month.
Primary endpoints: Change from baseline in the Female Sexual Function Index desire domain (FSFI-D) score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm Item 13 (FSDS-DAO-13) score.
Results: Bremelanotide significantly improved both co-primary endpoints versus placebo. FSFI-D scores increased by 0.5 points more than placebo in Study 1 and 0.6 points more in Study 2 (both p < 0.001). Sexual distress scores decreased by 0.7 points more than placebo across both studies.
Responder analysis: More women on bremelanotide reported meaningful improvements in desire. In a prespecified responder analysis, 34.4% of bremelanotide-treated women versus 22.6% on placebo achieved a clinically meaningful response on the desire domain.
Dosing patterns: Women in the trials used bremelanotide an average of 2-3 times per month, well below the maximum of eight doses per month. This usage pattern suggests the drug was used for specific occasions rather than as a regular therapy. The on-demand model is fundamentally different from flibanserin (Addyi), which requires daily oral dosing regardless of planned sexual activity.
What the trials did not measure: The RECONNECT trials excluded postmenopausal women, women with secondary causes of low desire (relationship problems, medication effects, depression), and women using hormonal contraceptives that contain estrogen. This means the approved population is narrower than the broader group of women who experience low sexual desire. The article on peptide therapeutics for female sexual dysfunction covers the wider treatment landscape.
The Regulatory Journey
PT-141's path to approval was not straightforward. Palatin Technologies initially developed the drug as an intranasal spray, but the FDA halted that program in 2008 after a Phase 3 trial showed transient increases in blood pressure that concerned regulators. The company reformulated bremelanotide as a subcutaneous injection at a lower dose (1.75 mg versus the original 20 mg intranasal dose), which produced less blood pressure elevation while maintaining efficacy.
The reformulated injectable version entered new Phase 3 trials (RECONNECT) in 2014 and received FDA approval in June 2019. The approval was specifically limited to premenopausal women with acquired, generalized HSDD, a deliberately narrow indication. The FDA's review noted that the drug's benefits were "modest" but that no other approved treatments addressed desire (as opposed to arousal) through a central nervous system mechanism.
Long-Term Safety Data
Simon and colleagues published 52-week safety and efficacy data in 2019, drawing from an open-label extension of the RECONNECT trials.[7]
The most common adverse event was nausea, reported by approximately 40% of patients. Most nausea episodes were mild to moderate and diminished with repeated dosing. Other common side effects included flushing (20%), headache (11%), and injection site reactions (6%).
Clayton and colleagues conducted a comprehensive safety analysis across the entire clinical development program in 2022. They found no evidence of cardiovascular events, no clinically meaningful changes in vital signs beyond transient blood pressure elevations lasting 2-4 hours post-dose, and no increase in melanocytic nevi (moles) during the trial period.[8] The PT-141 side effects article covers safety data in detail.
The FDA label carries a specific warning about focal hyperpigmentation of the face, gingiva, and breasts, observed in some patients. This effect is expected given the drug's melanocortin mechanism and is generally reversible upon discontinuation.
The discontinuation rate due to adverse reactions was 18% in the bremelanotide group versus 2% on placebo, with nausea accounting for most dropouts.
The Criticism: Effect Size and Clinical Significance
Not everyone agrees the trial results justify approval. Spielmans published a detailed reanalysis of the Phase 3 data in 2021, arguing that the effect sizes were small and the clinical significance questionable.[9]
His analysis found that the statistically significant differences on the primary endpoints translated to modest real-world effects. The average bremelanotide-treated woman experienced approximately one additional satisfying sexual event (SSE) per month compared to placebo. Spielmans also noted that the 18% discontinuation rate due to side effects meant that many women who received the drug stopped using it.
This criticism mirrors a broader debate about HSDD treatments, including the oral drug flibanserin (Addyi). The question is whether small average improvements on questionnaire-based endpoints represent meaningful clinical benefit for individual patients, or whether the statistical significance is driven by the large sample size.
Barakeh, Mdaihly, and Karaoui reviewed the full pharmacotherapy landscape for HSDD in premenopausal women in 2025, placing bremelanotide alongside flibanserin and emerging options like testosterone. They noted that both approved drugs have "modest efficacy with notable adverse effects," and that treatment selection should account for individual patient profiles, particularly the nausea burden with bremelanotide versus the CNS depression risk with flibanserin.[10]
PT-141 in Men: Off-Label and Under Study
PT-141's sexual effects were first discovered in men, and research on male applications has continued alongside the female-focused approval path.
Safarinejad and Hosseini published a randomized, double-blind, placebo-controlled trial in 2008 testing bremelanotide in men who had failed sildenafil (Viagra). Among 342 men with erectile dysfunction unresponsive to PDE5 inhibitors, bremelanotide produced a statistically significant improvement in erectile function compared to placebo. The authors concluded that the drug offered a "salvage therapy" option for PDE5 inhibitor non-responders, addressing a population that had no other pharmacological options at the time.[11]
The logic behind using a brain-targeting peptide for erectile dysfunction is that many cases of ED involve reduced desire or arousal drive, not just vascular insufficiency. PDE5 inhibitors only work when a man is already sexually aroused; they amplify the downstream signal but do nothing for the upstream motivation. Bremelanotide addresses the upstream component. Palatin Technologies has explored combination approaches, pairing bremelanotide with a PDE5 inhibitor to address both central drive and peripheral blood flow simultaneously. The PT-141 for male erectile dysfunction article covers the male evidence base in detail. The relationship between oxytocin and male sexual function provides additional context on peptide approaches to male sexuality.
An Unexpected Finding: Effects on Body Weight
Spana, Jordan, and Fischkoff reported in 2022 that bremelanotide reduced body weight in obese women during two Phase 1 randomized controlled trials. Melanocortin 4 receptors are central regulators of energy balance, and their activation suppresses appetite. The bremelanotide-treated group lost a mean of 1.7 kg more than placebo over 14 days, with the effect appearing dose-dependent.[12]
This finding is consistent with the known biology of MC4R. Loss-of-function mutations in the MC4R gene are the most common monogenic cause of obesity. The observation raises the question of whether melanocortin agonists could serve dual purposes, though bremelanotide's nausea profile and injectable delivery make it impractical for weight management in its current form. The MC4R and childhood obesity article covers the receptor's role in energy balance.
Practical Realities
Bremelanotide is administered as a 1.75 mg subcutaneous injection in the abdomen or thigh, at least 45 minutes before anticipated sexual activity. No more than one dose per 24 hours and no more than eight doses per month are recommended.
The drug requires refrigeration and comes in a prefilled autoinjector. It is not available as a pill. The injectable route limits uptake compared to oral alternatives, though the on-demand dosing model (rather than daily use like flibanserin) is preferred by some patients.
The wholesale acquisition cost as of 2025 is approximately $900-1,000 per month for eight doses. Insurance coverage remains inconsistent, and many patients pay out of pocket.
The Bottom Line
Bremelanotide (PT-141/Vyleesi) is an FDA-approved melanocortin peptide that treats hypoactive sexual desire disorder through a brain-based mechanism unrelated to blood flow drugs like Viagra. Phase 3 trials in 1,247 women showed statistically significant improvements in desire and reduced sexual distress, though the effect size is modest and nausea affects 40% of users. The drug traces back to a serendipitous discovery during tanning peptide research. Male applications, weight effects, and the ongoing debate about clinical significance continue to shape PT-141's evolving story.